Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 3.85
CTIX's Cash to Debt is ranked lower than
64% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. CTIX: 3.85 )
Ranked among companies with meaningful Cash to Debt only.
CTIX' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 4.00 Max: No Debt
Current: 3.85
F-Score: 4
Z-Score: 4.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -164.24
CTIX's ROE (%) is ranked lower than
89% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. CTIX: -164.24 )
Ranked among companies with meaningful ROE (%) only.
CTIX' s ROE (%) Range Over the Past 10 Years
Min: -319.44  Med: -277.22 Max: -235
Current: -164.24
-319.44
-235
ROA (%) -78.36
CTIX's ROA (%) is ranked lower than
82% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CTIX: -78.36 )
Ranked among companies with meaningful ROA (%) only.
CTIX' s ROA (%) Range Over the Past 10 Years
Min: -2870.38  Med: -215.64 Max: -104.45
Current: -78.36
-2870.38
-104.45
ROC (Joel Greenblatt) (%) -27671.64
CTIX's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. CTIX: -27671.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CTIX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -41215.38  Med: -37416.78 Max: -33618.18
Current: -27671.64
-41215.38
-33618.18
EBITDA Growth (3Y)(%) 30.10
CTIX's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. CTIX: 30.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CTIX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 5.30 Max: 81.7
Current: 30.1
0
81.7
EPS Growth (3Y)(%) 27.50
CTIX's EPS Growth (3Y)(%) is ranked higher than
82% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CTIX: 27.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CTIX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.9  Med: 50.90 Max: 94.9
Current: 27.5
-0.9
94.9
» CTIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CTIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 24.00
CTIX's P/B is ranked lower than
99.99% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 2.68 vs. CTIX: 24.00 )
Ranked among companies with meaningful P/B only.
CTIX' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 338.2
Current: 24
0
338.2
Current Ratio 1.08
CTIX's Current Ratio is ranked lower than
88% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. CTIX: 1.08 )
Ranked among companies with meaningful Current Ratio only.
CTIX' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.12 Max: 2.4
Current: 1.08
0.01
2.4
Quick Ratio 1.08
CTIX's Quick Ratio is ranked lower than
84% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. CTIX: 1.08 )
Ranked among companies with meaningful Quick Ratio only.
CTIX' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.12 Max: 2.4
Current: 1.08
0.01
2.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 120.00
CTIX's Price/Net Cash is ranked lower than
97% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: 6.04 vs. CTIX: 120.00 )
Ranked among companies with meaningful Price/Net Cash only.
CTIX' s Price/Net Cash Range Over the Past 10 Years
Min: 105.33  Med: 258.00 Max: 439
Current: 120
105.33
439
Price/Net Current Asset Value 120.00
CTIX's Price/Net Current Asset Value is ranked lower than
98% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: 6.40 vs. CTIX: 120.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CTIX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 79  Med: 219.50 Max: 258
Current: 120
79
258
Price/Tangible Book 120.00
CTIX's Price/Tangible Book is ranked lower than
98% of the 1048 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. CTIX: 120.00 )
Ranked among companies with meaningful Price/Tangible Book only.
CTIX' s Price/Tangible Book Range Over the Past 10 Years
Min: 79  Med: 137.50 Max: 219.5
Current: 120
79
219.5
Earnings Yield (Greenblatt) (%) -8.12
CTIX's Earnings Yield (Greenblatt) (%) is ranked lower than
51% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CTIX: -8.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CTIX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -10.45  Med: 0.00 Max: 0
Current: -8.12
-10.45
0

More Statistics

EPS $ -0.09
Beta1.76
Short Percentage of Float0.00%
52-Week Range $0.94 - 3.90
Shares Outstanding(Mil)118.50

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Cellceutix Corporation, formerly known as EconoShare was incorporated on August 1, 2005 in the State of Nevada and was organized for the purpose of developing a B2B website for an Asset Sharing market place and transaction system. On December 6, 2007, EconoShare, Inc. acquired Cellceutix Pharma, Inc., a privately owned Delaware corporation with Cellceutix Pharma becoming a wholly-owned subsidiary of EconoShare, Inc. As a result of the Exchange with Cellceutix Pharma, Inc., the Company has adopted the business plan of Cellceutix Pharma, Inc. and now is into an early stage developmental biopharmaceutical Company. It has acquired rights to seven (7) different pharmaceutical compound candidates that are designed for treatment of diseases which exist, or might exist in the future. The Company would initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin(tm), for the treatment of certain cancers. This compound is furthest along in in-vivo studies in small animals. Based on the results, the Company has decided to advance Kevetrin along the regulatory and clinical pathway. The Company's current portfolio of product candidates in pre-clinical development includes: (i) two (2) anti-cancer agents targeting multiple tumors; (ii) one (1) candidate targeting psoriasis; (iii) one (1) candidate targeting rheumatoid arthritis; (iv) one (1) candidate with potential for indications of osteo-arthritis/asthma; (v) one (1) candidate with a potential for indications of neurological disorders for the treatment of Multiple Sclerosis, Lou Gehrig Disease, and/or Parkinson's Disease; and (vi) a small molecule with potential for development to treat hypertensive emergency. Its product candidate, Kevetrin. Kevetrin is initially being developed to treat certain cancers. The Company is in the business of developing innovative small molecule therapies to treat diseases with significant medical need, particularly in the areas of cancer and inflammatory disease. The Company's compounds are still in preclinical development. It competes with biopharmaceutical firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to its operations. In the United States, drugs are subject to rigorous regulation by the United States Food and Drug Administration ('FDA'). The Federal Food, Drug and Cosmetic Act, and other federal and state statutes and regulations, govern the testing, manufacture, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion of its products.
» More Articles for CTIX

Headlines

Articles On GuruFocus.com
Interview with CEO of Cellceutix Corporation: Leo Ehrlich Nov 15 2011 

More From Other Websites
What are Investors Looking at - Research on American Green, Sunshine Biopharma, Portlogic Systems... Feb 02 2016
The Price Data Tells the Story -- Research Reports on American Green, Terra Tech, Cellceutix, and... Feb 01 2016
A Small-Cap Biotech With Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and... Jan 28 2016
Cellceutix Phase 2 Trial of New Oral Treatment for Psoriasis Nearing Completion Jan 25 2016
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic... Jan 22 2016
Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Pancreatic Cancer Jan 21 2016
Where We Are Headed - Complementary Research on Trans-Pacific Aerospace Company, Rubicon Minerals,... Jan 21 2016
Cellceutix Submits Briefing Book for Phase 2 Trial of p53 Targeting Drug for Ovarian Cancer Jan 19 2016
Brilacidin Lyophilized as Cellceutix Prepares to Bring First New Class of Antibiotic to Phase 3... Jan 14 2016
Factors Moving Markets - Analyst Notes on Rubicon Minerals, Cellceutix, Wolseley and Striker... Jan 14 2016
Cellceutix Invites All to Attend Its Live Webcast of Company's Presentation at Biotech Showcase 2016 Jan 05 2016
CELLCEUTIX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 21 2015
Cellceutix Stockholders Tour Company Facilities at First Annual Stockholder Meeting; Investors... Dec 17 2015
Cellceutix First Annual Shareholder Meeting December 15, 2015 Dec 14 2015
Cellceutix Completes Lab Testing of Brilacidin for Planned Phase 3 Trial for Acute Bacterial Skin... Dec 11 2015
CELLCEUTIX CORP Financials Dec 08 2015
Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of... Dec 01 2015
Cellceutix Retains Former Durata Executive Ronald Trust as Regulatory Affairs Consultant Nov 30 2015
FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis Nov 25 2015
Beyond the Chart, What Price Data Reveals - Research on Alcobra, Control4, Contango Oil & Gas, and... Nov 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK